| Filed On | Filing |
|---|---|
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, October 28, 2026 -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financi... |
| 28 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
Reconciliation and tie between Trust Indenture Act of 1939 and |
| 22 Sep 2026 |
8-K: Other Events
Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens |
| 29 Jul 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, July 29, 2026 -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial ... |
| 26 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 19, 2026, Viking Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 115,893,943 shares of the Company’s common stock outstanding as of March 20, 2026, the record date for... |
| 29 Apr 2026 |
8-K: Results of Operations and Financial Condition
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled -- |
| 11 Feb 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full Enrollment |
| 22 Oct 2025 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, October 22, 2025 -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financi... |
| 19 Aug 2025 |
8-K: Regulation FD Disclosure
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity |
| 23 Jul 2025 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, July 23, 2025 -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financia... |
| 27 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 20, 2025, Viking Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 112,288,759 shares of the Company’s common stock outstanding as of March 31, 2025, the record date for... |
| 23 Apr 2025 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, April 23, 2025 -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financi... |
| 23 Apr 2025 |
8-K: Changes in Registrant's Certifying Accountant; Other Events
We have read the statements made by Viking Therapeutics, Inc. under Item 4.01 of its Form 8-K |
| 11 Mar 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient |
| 05 Feb 2025 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, February 5, 2025 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its finan... |
| 04 Nov 2024 |
8-K: Regulation FD Disclosure
Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735 |
| 23 Oct 2024 |
8-K: Results of Operations and Financial Condition
Positive Phase 1b Results from VK0214 Study in X-ALD Demonstrate Safety, Tolerability and Reductions in Very Long-Chain Fatty Acids and Plasma Lipids |
| 24 Jul 2024 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, July 24, 2024 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financia... |
| 04 Jun 2024 |
8-K: Regulation FD Disclosure
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) |
| 23 May 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
On May 21, 2024, Viking Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved the Viking Therapeutics, Inc. 2024 Equity Incentiv... |
Loading...